Grown Rogue Reports Record Q3 2021 Results, 73% Gross Margin and 55% aEBITDA¹ Margin in Michigan
Grown Rogue International reported a positive net income of $0.24M for Q3 2021, marking a significant milestone in company history. Sales revenue soared to $3.03M, a 121% increase from Q2 2021. The company achieved an aEBITDA margin of 25% ($0.77M), up from 12% in the previous quarter. Indoor revenue surged by 277% to $2.81M. Michigan operations reported gross margins of 73% and aEBITDA margins of 55%. With fiscal Q4 guidance indicating 18-22% sequential revenue growth, Grown Rogue anticipates continued momentum in profitability and production efficiency.
- Net income of $0.24M for the first time in company history
- Sales revenue increased by 121% to $3.03M compared to Q2 2021
- aEBITDA margin rose to 25% ($0.77M) from 12% in Q2 2021
- Indoor revenue grew by 277% to $2.81M
- Michigan operations reported an industry-leading gross margin of 73% and an aEBITDA margin of 55%
- Seventh consecutive quarter of positive aEBITDA
- Increased indoor production run rates from 200 to 1,000 pounds per month
- Fiscal Q4 guidance predicts 18-22% sequential revenue growth
- None.
-
Positive Net Income of
for the first time in company history$0.24M -
Q3 2021 Sales Revenue of
versus$3.03M in Q2 2021, an increase of$1.37M 121% -
Q3 2021 aEBITDA1 margin of
25% ( ), versus$0.77M 12% ( ) in Q2 2021, an increase of$0.18M 330% ( )$0.59M -
Indoor Revenue of
, versus$2.81M in Q2 2021, an increase of$0.75M 277% -
Michigan operations (throughGolden Harvests, LLC ) report industry leading gross margins of73% (before fair value adjustments) and aEBITDA1 margins of55% -
Fiscal Q4 guidance of 18
-22% sequential revenue growth
Financial and Business Highlights
- Seventh consecutive quarter, including pro-forma results, of positive aEBITDA1
-
Company-record
59% gross margin before fair value adjustments - Increased indoor production run rates from 200 pounds/month in Q2 2021 to 1,000 pounds/month in Q3 2021
-
Grown Rogue partner,Canopy Management, LLC , exercised option and acquired60% controlling interest ofGolden Harvests, LLC (“Golden Harvests”) -
Subsequent to quarter-end,
Grown Rogue appointedRyan Kee as Chief Financial Officer -
Subsequent to quarter-end,
Golden Harvests and Pure Extracts Inc. formed a Joint Venture to Expand Product Offerings inMichigan -
Subsequent to quarter-end,
Grown Rogue issued an unsecured promissory note for .$800,000
“Just over a year ago,
Highlights by State
Oregon Operations
-
Revenue of
, a year over year increase of$1.28M 42% -
Indoor Revenue of
, a sequential increase of$1.06M 42% -
Product sale gross margins (before fair value adjustments) of
40% vs36% in Q2 2021 -
aEBITDA1 of approximately
$0.1M - Production run rate expected to increase from Q3 2021 of 600 pounds/month to 700 pounds/month in Q4 2021
- Expect a record outdoor harvest in Q4 of 4,000 to 4,500 pounds, compared to 2,300 pounds in the previous outdoor harvest
- Expect to end 2021 fiscal year with a cultivation run rate of approximately 12,000-14,000 pounds annually
Michigan Operations (through
-
Revenues of
, a sequential increase of$1.75M 27% versus pro-forma2 Q2 2021 -
aEBITDA 1 of
, a sequential increase of$0.96M 185% versus pro-forma2 Q2 2021 -
aEBITDA 1 margin of
55% versus pro-forma224% in Q2 2021 -
Continued construction to maximize output from the 80,000 square foot facility. 45,000 square feet are now in operation, with another 20,000 square feet expected to be online by
June 2022 - Added two new flower rooms during Q3 2021 which will produce approximately 1,400 pounds per year
- Production run rate expected to increase from Q3 2021 of 400 pounds/month to 550 pounds/month in Q4 2021
- Improved wholesale position in bulk flower sales from 20th in Q2 2021 to 16th in Q3 2021 and 12th for Q4 to date, according to MarketScape
-
Pre-packaged flower accounted for approximately
30% ofGrown Rogue sales, a50% increase, versus20% for the state pre-packaged flower sales, according to MarketScape -
Grown Rogue proprietary, nitrogen sealed, pre-packaged flower pricing averaged per pound vs market average sales price of$2,700 (according to MarketScape) a$2,250 20% premium illustrating our strong brand presence - Expect state market share to increase in fiscal 2022 as additional cultivation capacity comes online and the Company enters new product categories
Selected Financial Information (Complete financial tables have been filed on www.sedar.com)
(Dollars in |
|
|
||
Three Months Ended |
|
2021 |
2020 |
|
Reported Revenue |
$ |
3,029 |
904 |
|
Gross profit, excluding fair value items, as reported |
$ |
1,790 |
428 |
|
aEBITDA1 |
$ |
772 |
141 |
|
Net income (loss) per share |
$ |
- |
(0.01) |
|
Weighted Common Shares Outstanding -basic |
|
155,219 |
104,821 |
|
Three months ended |
|
|
|
|
aEBITDA Reconciliation |
2021 ($) |
2020 ($) |
Net income, as reported |
240,294 |
(794,072) |
Add back realized fair value amounts included in inventory sold |
198,540 |
626,522 |
Add back (less) unrealized fair value gain (loss) on growth of biological assets |
(649,907) |
(770,724) |
Add back amortization of property & equipment included in cost of sales |
186,149 |
115,331 |
Subtotal |
(24,924) |
(822,943) |
Add back accretion expense, as reported |
187,493 |
321,875 |
Add back amortization of intangible assets, as reported |
- |
5,980 |
Add back amortization of property and equipment, as reported |
55,610 |
61,959 |
Add back share-based compensation |
82,492 |
329,014 |
Add back interest expense, as reported |
48,828 |
96,880 |
Add back unrealized loss on marketable securities, as reported |
422,867 |
(69,064) |
Add back unrealized gain on derivative liability |
- |
- |
Derecognition of derivative liability |
- |
(244,572) |
Loss on debt restructure |
- |
462,213 |
Add back unrealized foreign exchange loss |
- |
- |
Loss on settlement of non-controlling interest |
- |
- |
aEBITDA |
772,366 |
141,342 |
|
Three months ended |
||
|
|
||
Cash Margin analysis |
Revenue $ |
Costs $ |
Margin % |
|
3,028,991 |
911,387 |
|
Indirect overhead allocations |
- |
27,492 |
-- |
Third party products |
- |
- |
-- |
Service revenues |
- |
- |
-- |
Asset depreciation included in COGS |
- |
186,149 |
-- |
Cost of packaging & other included in COGS |
- |
114,172 |
-- |
Total costs of finished cannabis inventory sold, as reported |
3,028,991 |
1,239,200 |
|
Realized fair value amounts in inventory sold, as reported |
-- |
198,539 |
-- |
Unrealized fair value (gain) on growth of biological assets, as reported |
-- |
(649,906) |
-- |
Totals, as reported |
3,028,991 |
787,833 |
|
|
Three months ended |
||
|
|
||
Cash Margin analysis - |
Revenue $ |
Costs $ |
Margin % |
|
1,746,991 |
330,251 |
|
Indirect overhead allocations |
- |
- |
-- |
Third party products |
- |
- |
-- |
Service revenues |
- |
- |
-- |
Asset depreciation included in COGS |
- |
49,645 |
-- |
Cost of packaging & other included in COGS |
- |
92,167 |
-- |
Total costs of finished cannabis inventory sold, as reported |
1,746,991 |
472,063 |
|
Realized fair value amounts in inventory sold, as reported |
-- |
242,966 |
-- |
Unrealized fair value (gain) on growth of biological assets, as reported |
-- |
(547,838) |
-- |
Totals, as reported |
1,746,991 |
167,191 |
|
|
Three months ended |
||
|
|
||
Cash Margin analysis - |
Revenue $ |
Costs $ |
Margin % |
|
1,282,000 |
581,136 |
|
Indirect overhead allocations |
- |
27,492 |
-- |
Third party products |
- |
- |
-- |
Service revenues |
- |
- |
-- |
Asset depreciation included in COGS |
- |
136,504 |
-- |
Cost of packaging & other included in COGS |
- |
22,005 |
-- |
Totals before fair value adjustments |
1,282,000 |
767,137 |
|
Realized fair value amounts in inventory sold, as reported |
-- |
(44,427) |
-- |
Unrealized fair value (gain) on growth of biological assets, as reported |
-- |
(102,068) |
-- |
Totals, as reported |
1,282,000 |
620,642 |
|
NOTES: |
|
1. |
|
The Company’s “aEBITDA” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines aEBITDA as the Company’s net income (loss) for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities and the effects of fair-value accounting for biological assets and inventory. The Company believes that this is a useful metric to evaluate its operating performance. |
|
2. |
|
The Company has provided Cash Margin Analysis to demonstrate the methodology for calculating its non-IFRS production cost and margin metrics. Cash production costs of |
|
3. |
|
The Company has provided unaudited pro-forma revenue information, which assumes that closed and pending mergers and acquisitions in 2020 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2020 for the Company and target companies. |
NON-IFRS FINANCIAL MEASURES
Cash production costs of
About
FORWARD-LOOKING STATEMENTS
This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company into
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.
SAFE HARBOR STATEMENT
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company’s Form 20-F and 6-K filings with the
The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
For further information on
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005389/en/
Chief Executive Officer
obie@grownrogue.com
Investor Relations Desk Inquiries
invest@grownrogue.com
(458) 226-2100
Source:
FAQ
What were Grown Rogue's Q3 2021 financial results?
How did Grown Rogue's aEBITDA margin change in Q3 2021?
What is Grown Rogue's expected revenue growth for fiscal Q4?
What was the indoor revenue for Grown Rogue in Q3 2021?